Ignota Labs uses artificial intelligence to address a significant inefficiency in drug development: more than half of all clinical trials fail due to safety issues. The Cambridge-based company, founded in 2021, has developed SAFEPATH, an AI platform that combines machine learning with multimodal data integration to understand the mechanisms behind drug toxicity and identify interventions to rescue promising candidates that have stalled in preclinical and early clinical stages.
The company's founders bring experience from Google DeepMind, Eli Lilly, AstraZeneca, and leading academic institutions. Ignota Labs has raised $6.9m in seed funding led by Montage Ventures and AIX Ventures, and has received recognition including the Royal Society of Chemistry's Emerging Technologies Competition award and Sanofi's iDEA-Tech Award.
The platform applies computational toxicology and computational biology to analyse safety data across preclinical, Phase 1, and Phase 2 development stages, with the aim of accelerating the turnaround of drugs that would otherwise be abandoned due to safety concerns.
